MYGN
MYRIAD GENETICS INC
NASDAQ · Healthcare · Medical - Diagnostics & Research · US
$3.89
−6.04%Forward multiples
Based on analyst estimates
- P/E forward
- —
- P/E 2026E
- —
- P/E 2027E
- —
- P/E 2028E
- —
- P/S forward
- 0.47x
Trailing multiples
Trailing twelve months
- P/E TTM
- —
- PEG TTM
- —
- Price / book
- 1.22x
- Price / sales
- 0.46x
- Price / cash flow
- 48.32x
Enterprise value
- Enterprise value
- $467.4M
- EV / sales
- 0.58x
- EV / EBITDA
- -10.34x
- EV / EBIT
- -4.74x
- Market cap
- $372.1M
Trailing, forward and enterprise-value multiples for the requested listing · Data as of Jun 1, 2026